Do new migraine pills actually satisfy patients?

NCT ID NCT05827887

Ongoing Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This study aims to see how satisfied patients are with two already-approved migraine medications, ubrogepant and atogepant, when used in everyday life. It will follow about 200 adults in Israel who are prescribed one of these drugs by their doctor for 90 days. The main goal is to measure how many patients report being 'satisfied' or 'extremely satisfied' with their treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Assuta Ashdod Medical Center /ID# 260020

Ashdod, Southern District, 7747600, Israel
Clalit HMO /ID# 257364

Gani Tikva, 5591236, Israel
Edith Wolfson Medical Center /ID# 269740

Holon, Central District, 5822012, Israel
Hadassah Medical Center-Hebrew University /ID# 257352

Jerusalem, 91120, Israel
Maccabi Healthcare Services /ID# 254171

Kfar Saba, Central District, 4420123, Israel
Meir Medical Center /ID# 254170

Kfar Saba, Central District, 4428164, Israel
Shaare Zedek Medical Center /ID# 254169

Jerusalem, Jerusalem, 91031, Israel
Soroka University Medical Center /ID# 254551

Beersheba, Southern District, 8410101, Israel
Tel Aviv Sourasky Medical Center /ID# 263089

Tel Aviv, Tel Aviv, 6423906, Israel
The Chaim Sheba Medical Center /ID# 254550

Ramat Gan, Tel Aviv, 5265601, Israel
ZIV Medical Center /ID# 257360

Safed, Northern District, 13100, Israel

Conditions

Explore the condition pages connected to this study.

MIGRAINE